Injectable Ovalbumin-Based Composite Implant for Photothermal Tumor Therapy

Graphical Hardboiled : A multifunctional hydrogel implant based on ovalbumin has been designed that can simultaneously deliver a photothermal transducing agent (polydopamine) and a chemotherapeutic (doxorubicin) and/or a contrast agent (iohexol) to tumors. It is anticipated that the multifunctional implant, not showing obvious toxicity to healthy tissue, could be a promising system for synergistic cancer treatment. Polymeric hydrogels with three-dimensional network structures have found tremendous applications in biomedicine. Herein, we report the synthesis of a multifunctional implant based on ovalbumin (OVA) as a carrier capable of synergistically delivering a photothermal transducing agent (polydopamine, PDA) to tumors. The formation of PDA was achieved by utilizing the basicity of OVA, whereas the formation of the hydrogel implant was achieved through the in vitro/in vivo near-infrared (NIR) laser-induced hyperthermia of PDA. The as-prepared PDA@OVA implant exhibits high photothermal conversion efficiency (38.7 %). Once implanted in vivo, the OVA-based implant shows great versatility in the treatment of malignant tumors. Furthermore, a chemotherapeutic (doxorubicin, DOX) and a contrast agent (iohexol), dispersed in the OVA solution in advance, can also be firmly entrapped in the hydrogel along with the hydrogel formation. It is anticipated that the multifunctional OVA-based implant, not showing any obvious toxicity to healthy tissue, could be a promising system for synergistic cancer treatment.